Kimberly-Clark Corporation manufactures and markets personal care products, operating through two segments: North America and International Personal Care. The North America segment offers disposable diapers, training and youth pants, swimpants, baby wipes, feminine and incontinence care products, reusable underwear, facial and bathroom tissue, paper towels, napkins, wipers, tissue, towels, soaps and sanitizers, and other related products under brands such as Huggies, Pull-Ups, Goodnites, Kotex, Poise, Depend, Kleenex, Scott, Cottonelle, Viva, and Wypall. The International Personal Care segment provides baby and child care, adult care, and feminine care products, including disposable diapers, training and youth pants, swimpants, baby wipes, feminine and incontinence care products, reusable underwear, and other related products under brands such as Huggies, Kotex, Goodfeel, Intimus, and Depend. The company sells household products directly to supermarkets, mass merchandisers, drugstores, warehouse clubs, variety and department stores, and other retail outlets, as well as through distributors and e-commerce; professional use products are sold through distributors, directly to manufacturing, lodging, office building, food service, and high-volume public facilities, and through e-commerce. Founded in 1872, Kimberly-Clark is headquartered in Dallas, Texas.
Kenvue deal advances but regulatory and earnings risks weigh on KMB
▼
Q2 earnings beat but 2026 outlook cut on China allegations Kimberly-Clark beat profit expectations but missed revenue and lowered its full-year outlook, citing profit pressure from false diaper quality allegations in China. The stock trades below analyst targets, and the lowered guidance signals weaker near-term earnings, which pushes the price down.
This is the core earnings event of the period and directly explains why KMB is under pressure.
◆
China antitrust review deepens, adding delay risk to Kenvue deal China's market regulator moved the $49 billion Kenvue acquisition into a phase 2 review, which could delay or change the deal. Even though shares rose slightly that day, a longer review creates uncertainty about whether the deal closes on time and on the expected terms.
This is a new regulatory hurdle that could affect the deal's timing and value, a key driver for KMB.
◆
EU approval sought for Kenvue deal, another regulatory step Kimberly-Clark asked the European Union for permission to buy Kenvue, moving the deal into another review stage. The EU filing is a request, not an approval, so the outcome and any conditions remain uncertain, keeping a cloud over the deal's completion.
This is a new regulatory development that adds to the deal's uncertainty and is not yet in earlier reports.
◆
Kenvue deal nears close but integration and financial risks remain The Kenvue combination has cleared shareholder and U.S. antitrust hurdles and is expected to close in Q4 2026, but Kenvue's recent results showed margin pressure from inflation and tariffs, and the deal still faces foreign approvals and execution risk. The benefits may not be fully realized, which could limit upside for KMB.
This summarizes the latest status and risks of the deal, a major factor for KMB's future earnings and stock price.
Q3 2026
▲2▼2
Kimberly-Clark's Kenvue bet meets China and cost setbacks
▲
Kenvue acquisition adds major brands Kimberly-Clark agreed to buy Kenvue for $48.7 billion, adding Tylenol and Listerine. The deal is expected to create cost savings and more sales, expanding the company's consumer health business.
This is the biggest new event of the quarter and a key positive driver.
▲
Defensive appeal and dividend strength Kimberly-Clark's everyday products, 4.7% dividend yield, and 54-year record of raising dividends attract income investors. The stock also trades below its usual valuation, offering a margin of safety.
This explains why investors might still favor the stock despite risks.
▼
Regulatory and integration risks for Kenvue deal The Kenvue deal faces reviews in China and the EU that could delay or change it. Integrating Kenvue also brings execution challenges, and Kenvue itself struggles with inflation and tariffs pressuring its profit margins.
These are major new risks that could hurt the deal's success and KMB's stock.
▼
Outlook cut on China allegations and cost pressures Kimberly-Clark lowered its 2026 outlook after China diaper-quality claims and weaker revenue. A distribution-center fire, Middle East conflict, and higher oil prices are adding costs, weighing on results.
This directly explains the negative revision and operational headwinds this quarter.
News & notes movingKMB
United States
KMB
Kimberly-Clark Launches Exchange Offers for Kenvue Notes
Kimberly-Clark has launched exchange offers and consent solicitations for Kenvue's outstanding notes tied to its pending acquisition of the company. The proposal gives Kenvue bondholders the option to swap existing securities into new Kimberly-Clark issued notes on specified terms, and the consent solicitations seek bondholder approval to amend certain covenants in Kenvue's current debt documents as part of the transaction process. The exchange offers include new Kimberly-Clark notes plus cash and early participation premiums, effectively asking bondholders to accept Kimberly-Clark as the primary borrower on refreshed terms. Kimberly-Clark, a US household products manufacturer with a market value of about $32.9b, is seeking to simplify the debt structure around the pending Kenvue acquisition and bring those obligations directly onto its own balance sheet. The clearest early sign of success will be the level of noteholder participation and whether Kimberly-Clark secures the majority consents needed to strip restrictive covenants from the Kenvue indenture.
KMB · Capital · Neutral Kimberly-Clark launches exchange offers and consent solicitations to move Kenvue's notes onto its own balance sheet as part of the pending acquisition.
KVUE · Capital · Neutral Kenvue bondholders are offered swaps into new Kimberly-Clark notes and asked to approve covenant amendments tied to Kimberly-Clark's pending acquisition of Kenvue.
Kimberly-Clark Forms Arbex Joint Venture With Suzano for Hygiene and Tissue
Kimberly-Clark Corporation has formed Arbex, a strategic joint venture with Suzano that combines Suzano's scale and capabilities with Kimberly-Clark's commercial capabilities and tissue-making knowledge to create a world-class global competitor in the hygiene and tissue business. Kimberly-Clark said the partnership is a strategic combination rather than an effort to move away from an existing problem or challenge, and management expects its clear focus on global personal care to help drive execution as Arbex moves forward. The company reported sequential improvements and double-digit gains across International Personal Care markets including India, Southeast Asia and Indonesia, with diaper market share gains of 390 basis points in Indonesia and 70 basis points in Brazil. KMB stock has lost 11.2% in the past three months compared with the industry's decline of 1.3%, and trades at a forward price-to-earnings ratio of 13.38 versus the industry's average of 18.52. The Zacks Consensus Estimate for KMB's current fiscal-year earnings implies a year-over-year decline of 2.4%, while next fiscal year earnings imply growth of 2.1%.
KMB · Capital · Positive Kimberly-Clark formed the Arbex joint venture with Suzano, a strategic combination creating a global hygiene and tissue competitor.
KMB · Demand · Positive Reported double-digit gains in International Personal Care with diaper market share gains in Indonesia and Brazil.
Arbex · Capital · Positive Arbex is the newly formed joint venture between Kimberly-Clark and Suzano in hygiene and tissue.
Kimberly-Clark to Sell Assets Over $40 Billion Kenvue Deal EU Antitrust Concerns
Kimberly-Clark plans to sell assets tied to its planned US$40b acquisition of consumer products group Kenvue in order to address European Union antitrust concerns. The disposals target overlaps in consumer health and personal care brands, with asset sale discussions focused on EU markets where regulators flagged competition issues during their ongoing review of the Kenvue deal. Kimberly-Clark, a US household products group with a market cap of about US$32.6b, earns its money from personal care brands that sit close to Kenvue's consumer health and hygiene lines, which is exactly where regulators are probing for competitive overlap in Europe. The planned Kenvue acquisition, together with the targeted EU disposals, pushes Kimberly-Clark closer to Procter & Gamble and Colgate-Palmolive in terms of breadth, while the asset sales suggest management is prepared to trim overlap to keep the deal on track. Selling brands to satisfy regulators may reduce competitive pressure, but it also shrinks the pool of potential synergies and places more weight on flawless integration and disciplined marketing to maintain pricing power.
KMB · Regulation · Neutral Kimberly-Clark plans EU asset sales to address antitrust concerns over its $40B Kenvue acquisition, trimming overlap but reducing synergies.
KVUE · Regulation · Neutral Kenvue is the acquisition target whose deal faces EU antitrust review, prompting Kimberly-Clark's planned asset disposals.
Kimberly-Clark Plans Low Single-Digit Price Hikes to Offset $150 Million Input Cost Headwind
Kimberly-Clark Corporation is taking targeted pricing actions alongside a broader set of measures to manage rising input costs, with management estimating gross input cost headwinds of approximately $150 million for the second half of the year. That follows approximately $50 million of inflationary headwinds in the second quarter, primarily related to higher oil-linked input costs and some impacts from the L.A. distribution center. Management said the magnitude of the pricing actions is expected to be in the low single digits, primarily in North America, while pricing actions globally will vary by geography. The pricing actions are already in the marketplace and form part of the company's effort to maintain PNOC discipline over time, with Kimberly-Clark continuing to follow a principle of keeping pricing net of cost neutral over time. Alongside pricing, the company is delivering its highest level of productivity to date and actively managing negotiations and contracts with vendors and suppliers, using multiple levers rather than relying solely on revenue growth management.
KMB · Pricing · Neutral Kimberly-Clark plans low single-digit price hikes in North America to offset ~$150M input cost headwinds, keeping pricing net of cost neutral.
AI Stocks Plunge, 10-Year Treasury Yield Tops 5%, Oil Surges Over 4%
Wall Street traded lower on Monday as AI-related shares tumbled after executives at leading U.S. AI companies called for a slower pace of development, with SoftBank falling as much as 13.2% in Japan, SK Hynix dropping 6.4%, Samsung Electronics declining 4%, and in the U.S. Nvidia slipping 2.4% premarket while Micron and AMD each fell 5% and Broadcom dropped 3.4%, following an essay Saturday by Anthropic CEO Dario Amodei arguing that progress on improving AI model capabilities should be slowed. Crude oil surged, with front-month Nymex crude jumping 4.3% to $104.37/bbl and Brent rising 4.5% to $109.32/bbl, after Persian Gulf countries called off a planned meeting with Iran on reopening the Strait of Hormuz and a Friday drone strike knocked out Saudi Arabia's East-West pipeline, which feeds the Red Sea port of Yanbu and moves 4M bbl/day; traders estimate the closure could cut off up to 4% of global oil supply, with Yanbu storage covering just 5-7 days of exports. The benchmark 10-Year Treasury yield reached 5% for the first time since October 23, 2023, adding 3 basis points Monday, while the 2-Year yield rose 4 basis points to about 4.66% and the 30-Year added 2 basis points to 5.37%. Kimberly-Clark is preparing possible asset sales to resolve European Union competition concerns over its proposed $40 billion acquisition of Kenvue, with the European Commission expected to notify the company of its concerns this week ahead of a preliminary review deadline on September 29.
000660.KO · Technology · Negative SK Hynix dropped 6.4% amid the AI-related selloff following calls to slow AI model development.
005930.KO · Technology · Negative Samsung Electronics declined 4% as AI-related shares tumbled on calls to slow AI development.
9984.JP · Technology · Negative SoftBank fell as much as 13.2% in Japan as AI-related shares tumbled on calls to slow AI development.
NVDA · Technology · Negative Anthropic CEO's call to slow AI development drove AI-related shares lower, with Nvidia slipping 2.4% premarket.
KMB · Regulation · Negative Kimberly-Clark may need asset sales to resolve EU competition concerns over its $40B Kenvue acquisition, with the Commission set to notify concerns.
KVUE · Regulation · Neutral Kenvue is the target of Kimberly-Clark's $40B acquisition facing EU competition concerns, but no direct impact on Kenvue is stated.
Kimberly-Clark has extended its dividend increase streak to 54 consecutive years with its Q2 2026 declaration, even as it works to close a $48.7 billion acquisition of Kenvue by the end of 2026. The board raised the quarterly payout to $1.28 per share, up from $1.26 in late 2025 and $1.22 in 2024, for an annualized forward dividend of $5.12, with the next payment scheduled for October 2, 2026. Kimberly-Clark enters the transition with $956 million in cash and total debt of roughly $6.52 billion as of June 30, 2026, while full-year 2025 operating cash flow of $2.777 billion covered $1.138 billion of capex and $1.66 billion of dividends before any Kenvue-related financing. CEO Mike Hsu called the transaction a powerful next step in the company's transformation and a unique, generational value creation opportunity, and management said roughly 50 teams and 600 people are working on synergy planning. Q2 2026 adjusted EPS of $2.12 beat the $2.01 estimate and adjusted gross margin expanded 190 basis points to 38.8%, but the stock is down 20.36% over the past year to $98.15, pushing the yield near 5.16%.
KMB · Capital · Positive Kimberly-Clark raised its quarterly dividend to $1.28, extending its 54-year streak, while also beating Q2 EPS estimates with margin expansion.
KVUE · Capital · Neutral Kenvue is the target of Kimberly-Clark's $48.7 billion acquisition, with the deal still pending close by end of 2026.
Kimberly-Clark Seeks EU Approval for $40 Billion Kenvue Deal
Kimberly-Clark has requested European Union permission for its proposed $40 billion takeover of Kenvue, moving the transaction into another stage of regulatory review. The deal, first announced in November 2025, would combine Kimberly-Clark with consumer-health brands including Tylenol, Listerine, Aveeno, and Neutrogena, creating a company with roughly $32 billion in annual revenue and projected annual cost savings of $2.1 billion. The EU filing is a request for clearance, not an approval, and does not indicate when a decision will come or whether conditions may be imposed. Kimberly-Clark originally expected the deal to close in the second half of 2026, but that remains a forecast. The company faces execution risks from integrating two large businesses and delivering the projected savings, which represent about 6.6% of the combined revenue.
Kenvue-Kimberly-Clark Deal Nears Closing With Risks Ahead
Kenvue Inc. is moving closer to its planned combination with Kimberly-Clark Corporation, with shareholder approvals secured and the U.S. antitrust waiting period expired, though the cash-and-stock transaction is expected to close in the fourth quarter of 2026, subject to remaining foreign regulatory approvals and customary conditions. Kenvue shareholders are expected to receive 0.14625 Kimberly-Clark shares plus $3.50 in cash for each Kenvue share, and they are expected to own about 46% of the combined company on a fully diluted basis after closing. Kimberly-Clark has announced a post-closing organizational structure, but Kenvue is not providing forward-looking financial guidance while the deal is pending, and expected benefits may not be realized. Recent results show execution challenges: second-quarter 2026 net sales rose 3% to $3,955 million and organic sales increased 1.6%, but adjusted earnings of 31 cents per share missed the Zacks Consensus Estimate of 32 cents, while adjusted gross margin fell 70 basis points to 60.2% due to inflation, tariffs, and unfavorable transactional foreign exchange. Self Care remains a pressure point with first-half organic sales down 0.9%, while Skin Health and Beauty provided a stronger offset with organic sales up 4.4% and segment adjusted operating income rising 46.9% to $354 million. The balance sheet adds risk: Kenvue had $8.5 billion of total debt and $1.1 billion of cash as of June 28, 2026, and the 2026 restructuring program is expected to carry approximately $250 million of pre-tax charges before delivering approximately $200 million of annualized pre-tax gross cost savings. Legal and macro pressures persist, including the Second Circuit vacating the prior acetaminophen judgment in July 2026 and remanding the litigation, talc-related liabilities outside the U.S. and Canada, and annualized gross tariff exposure estimated at approximately $80 million. Major milestones are complete, but the expected fourth-quarter closing still carries regulatory, operational, and financial risk.
KVUE · Capital · Negative Q2 adjusted EPS missed estimates, gross margin fell due to inflation, tariffs, and FX; debt and restructuring charges add risk.
KMB · Capital · Neutral Merger nearing close with risks; deal expected to close Q4 2026, but benefits may not be realized.
China antitrust regulator deepens review of Kimberly-Clark Kenvue deal
China's State Administration for Market Regulation has moved its evaluation of Kimberly-Clark's planned $49 billion acquisition of Kenvue into a phase 2 review, according to traders citing a Capitol Forum report. The deal was expected to have a quick review, but a complaint by an antitrust expert at Beijing's Tsinghua University and a safety controversy involving Kimberly-Clark and other diaper makers may have triggered the in-depth review. The transaction, announced in January, is expected to close in the second half of 2026 and would create a projected $32 billion revenue health and wellness leader. Shares of Kimberly-Clark advanced 1.3% on Wednesday, while Kenvue rose 1.1%.
Kimberly-Clark's 54-Year Dividend Streak and Kenvue Deal Draw Income Investor Attention
Kimberly-Clark raised its quarterly dividend from $1.26 to $1.28 per share in January 2026, bringing the annual payout to $5.12 per share and a yield of about 4.6% with the stock near $110. The company has increased its dividend for 54 consecutive years and paid dividends for 92 years, supported by essential brands like Huggies, Kleenex, and Scott that hold No. 1 or No. 2 positions in roughly 70 countries. Cash from operations including discontinued operations reached $1.7 billion in the first half of 2026, up from $1.1 billion a year earlier, while capital spending rose to $776 million from $401 million and dividends paid totaled $843 million. Management expects about $2 billion in adjusted free cash flow for 2026, roughly in line with 2025, despite plans to spend about $1.3 billion on capital investments. The pending Kenvue acquisition, expected to close in the fourth quarter of 2026, is projected to add about $1.9 billion in cost synergies and another $500 million in profit from revenue synergies within three to four years of closing, though integration risks remain.
Kimberly-Clark Launches Hesperaloe Fiber Program for Hygiene Products
Kimberly-Clark has launched a proprietary program using hesperaloe, an arid climate plant, to develop next-generation materials for hygiene products. The initiative aims to support sustainability goals and supply chain resilience as consumer and regulatory attention on ESG continues to rise. The company, with a market cap of $36.8b, relies on large volumes of fiber-based materials for its personal care portfolio. The program is positioned to support a premium, science-led hygiene strategy and could differentiate products from competitors like Procter & Gamble and Colgate-Palmolive. Analysts have flagged debt levels and dividend coverage as pressure points, and a large-scale ramp-up of a new materials supply chain could tighten financial flexibility if returns take time to show.
Kenvue misses quarterly estimates as inflation and tariffs squeeze margins
Kenvue narrowly missed Wall Street estimates for second-quarter results as inflation, tariffs, and currency-related costs squeezed margins. Adjusted gross margin fell to 60.2% from 60.9% a year earlier, while adjusted profit came in at 31 cents per share, just below the 32-cent analyst estimate. Quarterly sales rose 3% to $3.96 billion, slightly missing the $3.97 billion consensus. The consumer-health company, currently in the midst of a $40 billion buyout by Kimberly-Clark, expects the deal to close in the fourth quarter of 2026.
Kimberly-Clark Trades at Discount After Q2 Earnings Beat and Lowered 2026 Outlook
Kimberly-Clark shares are trading at a discount to internal fair value estimates and the average analyst target after second quarter 2026 earnings beat profit expectations but missed on revenue, and management lowered the full year outlook. The company flagged ongoing profit pressure from false diaper quality allegations in China, contributing to a 12.80% decline in one-year total shareholder return despite a 12.48% gain over the past 90 days. A narrative fair value estimate of $117.00 per share suggests the stock is modestly undervalued at its last close of $111.57, based on steady revenue growth, a step up in profitability, and a future earnings multiple below the current industry level. The valuation gap is linked to specific earnings and margin expectations under a 7.11% discount rate, though risks remain from private label competition and weaker consumer demand in key international markets.
Kimberly-Clark Posts Mixed Q2 Results and Unveils Hesperaloe Fiber Program
Kimberly-Clark reported second-quarter 2026 sales of US$4,189 million, up slightly from US$4,163 million a year earlier, while net income fell to US$345 million from US$509 million, and also announced a new Alternative Natural Fiber program using the drought-resistant hesperaloe plant. The hesperaloe-based materials platform is patented and could reshape the company's fiber sourcing and product differentiation over time, though its near-term financial impact appears limited. The company's investment narrative projects US$18.4 billion in revenue and US$2.7 billion in earnings by 2029, requiring 3.5% annual revenue growth and a roughly US$1.0 billion earnings increase from the current US$1.7 billion. Some analysts have set a more optimistic revenue target of about US$21.9 billion and earnings of US$2.8 billion by 2029, a bar that may be challenged or reinforced by the hesperaloe push and recent margin trends.
Kimberly-Clark, Westlake Chemical Partners, Eagle Materials, Robert Half, Western Union, and Northern Oil and Gas declare dividends
Several companies announced dividend declarations. Kimberly-Clark declared a regular quarterly dividend of $1.28 per share, payable on October 2, 2026 to stockholders of record on September 4, 2026. Westlake Chemical Partners declared a distribution of $0.4714 per unit, its 48th quarterly distribution since its initial public offering, payable on August 28, 2026 to unit holders of record on August 13, 2026. Eagle Materials declared a quarterly cash dividend of $0.25 per share, payable on October 13, 2026 to stockholders of record on September 14, 2026. Robert Half declared a quarterly cash dividend of $0.59 per share, payable on September 15, 2026 to shareholders of record on August 25, 2026. Western Union declared a quarterly cash dividend of $0.235 per common share, payable on September 30, 2026 to stockholders of record on September 16, 2026. Northern Oil and Gas declared a cash dividend of $0.45 per share, equal to the prior quarterly dividend, payable on October 30, 2026 to stockholders of record on September 29, 2026.
Kenvue's Brand Strength and Growth Drivers Shape Its Future Outlook
Kenvue Inc. remains a closely watched consumer health name as investors weigh trusted brands, improving margins and a major pending transaction. In the first quarter of 2026, adjusted gross margin expanded 80 basis points to 60.8% and adjusted operating margin improved 420 basis points to 24%, driven by supply-chain productivity and cost optimization actions. Skin Health and Beauty net sales increased 8.4%, with organic sales up 5%, supported by volume growth and innovation such as Neutrogena's entry into sun care in select EMEA markets. The pending cash-and-stock combination with Kimberly-Clark Corporation, under which Kenvue shareholders are expected to receive 0.14625 Kimberly-Clark shares plus $3.50 in cash per Kenvue share, has received shareholder approvals and U.S. antitrust clearance, with closing expected in the second half of 2026. The stock currently carries a Zacks Rank #3 (Hold), with Value, Growth and VGM Scores of C and a Momentum Score of D, reflecting a balanced near-term view.
KVUE · Capital · Positive Improved margins (gross +80bps, operating +420bps) and pending acquisition by Kimberly-Clark with shareholder and antitrust approvals.
KMB · Capital · Positive Pending combination with Kenvue is a strategic M&A transaction that expands Kimberly-Clark's consumer health portfolio.
Adult Diapers Market to Reach USD 32.19 Billion by 2035
The global adult diapers market is projected to grow from USD 14.16 billion in 2025 to USD 32.19 billion by 2035, at a compound annual growth rate of 8.22 percent, according to a new report by SNS Insider. North America held a 33 percent revenue share in 2025, with the U.S. market alone valued at USD 4.39 billion and expected to reach USD 8.79 billion by 2035. Europe was valued at USD 4.09 billion in 2025 and is forecast to hit USD 8.82 billion by 2035, while Asia-Pacific is set to be the fastest-growing region with a CAGR of 10.52 percent. Pull-up pants led product types with a 39 percent market share, retail pharmacies dominated distribution with 34 percent, urinary incontinence accounted for 56 percent of applications, and homecare settings captured 48 percent of end-user demand. Key players include Essity, Kimberly-Clark, Unicharm, and Ontex, with recent innovations focusing on improved absorbency, skin protection, and sustainable materials.
Jim Cramer Says Kimberly-Clark’s Acquisition of Kenvue Creates a High-Margin Powerhouse
Jim Cramer highlighted Kimberly-Clark as a defensive holding on CNBC's Mad Money, citing its acquisition of Kenvue, Johnson & Johnson's former consumer health business. The deal adds brands like Tylenol, Neutrogena, Listerine, and Band-Aids, creating a high-margin powerhouse with steady cash flow through economic cycles. Kimberly-Clark trades at roughly 14 times earnings, near its lowest multiple in a decade, and offers a 4.74% dividend yield after raising its quarterly payout to $1.28 per share, backed by 54 consecutive years of dividend increases. Cramer sees the stock as a long-term opportunity with potential upside from the Kenvue integration, though he does not expect a blowout second-quarter report on August 4th. Institutional investors own about 93% of the company, while a 14.5% short float could fuel a squeeze if integration results beat expectations.
Kimberly-Clark's 54-Year Dividend Streak and Kenvue Deal Make It a Buy
Kimberly-Clark, a Dividend King with 54 consecutive years of dividend increases, offers a 4.7% yield and is positioned for solid returns following a strategic shift. The company recently formed a joint venture called Arbex with pulp supplier Suzano, offloading its lower-margin paper-towel and tissue business to focus on higher-margin personal-care products while retaining licensing royalties. This move frees up resources to integrate its pending acquisition of Kenvue, a consumer health company spun off from Johnson & Johnson in 2023, which Kimberly-Clark expects will generate approximately $1.9 billion in cost synergies and roughly $500 million in profit from revenue synergies within three to four years of closing. Analysts have a median price target of $113 per share, implying 5% upside, and the stock trades at 14 times earnings.
KMB · Capital · Positive Kimberly-Clark formed a JV to offload lower-margin business and expects $1.9B cost synergies and $500M profit from Kenvue acquisition, with a 4.7% yield and 54-year dividend streak.
KVUE · Capital · Positive Kenvue is being acquired by Kimberly-Clark, which expects significant synergies; the deal is pending and viewed positively.
Kimberly-Clark and Suzano Joint Venture Arbex Begins Independent Operations
Arbex, the joint venture formed by Kimberly-Clark Corp and Suzano, started operating as an independent company on July 1. The $3.4 billion joint venture is positioned to pursue opportunities as an international tissue and hygiene company with operations in more than 70 markets, producing and selling leading global and regional brands including Kleenex, Scott, Cottonelle, Andrex, and Viva. It has assumed ownership of assets previously run by Kimberly-Clark's International Family Care & Professional business unit, which includes 22 manufacturing sites in 14 countries. Earlier on June 17, Piper Sandler reiterated a Buy rating on Kimberly-Clark Corp and raised the price target to $121 from $115, citing an incrementally favorable cost outlook and strong productivity momentum.
Arbex · Capital · Positive Arbex begins independent operations as a $3.4B joint venture, positioned to pursue international tissue and hygiene opportunities.
KMB · Capital · Positive Piper Sandler reiterated Buy rating and raised price target to $121, citing favorable cost outlook and productivity momentum.
Kimberly-Clark's Innovation Strategy Drives 3% Volume and Mix Growth in First Quarter
Kimberly-Clark reported that its innovation-led strategy delivered a 3% improvement in volume plus mix growth in the first quarter of fiscal 2026, marking two consecutive years of broad-based gains. The company emphasized that these improvements were driven primarily by product innovation rather than promotional activity, with promotional programs designed only to support product launches and accelerate adoption. In the quarter, promotions centered on the enhanced Snug & Dry offering, which features a softer feel from a redesigned absorbent core, contributing to higher household penetration and improved product velocities. Kimberly-Clark is building market share across its key focus areas of Baby Care, Women's Health, and Active Aging by consistently introducing differentiated products that address evolving consumer needs. The company's continued investment in consumer-centric innovation is reinforcing its competitive position and supporting sustainable, profitable organic growth over the long term.
Four Dividend Kings Are Crushing the S&P 500 in 2026 and Still Have Big Upside Potential
Four Dividend Kings are significantly outperforming the S&P 500's 9% gain in 2026 while offering reliable dividends backed by over 50 consecutive years of increases. Target surged 32% year to date and still trades at a cheap valuation with a 3.56% dividend yield. Colgate-Palmolive extended its 63-year dividend growth streak with a roughly 20.4% gain. Coca-Cola rose more than 16%, extending its 64-year dividend streak, and Kimberly-Clark advanced over 13% while yielding 4.41% and pursuing a $48.7 billion acquisition of Kenvue. All four stocks are rated Buy by top Wall Street firms.
Church & Dwight vs. Kimberly-Clark: Which Consumer Goods Stock Is a Better Buy in 2026?
Church & Dwight and Kimberly-Clark present contrasting investment cases in the household products market for 2026. Church & Dwight reported fiscal 2025 revenue of nearly $6.2 billion, a 1.6% increase, with net income of approximately $736.8 million and a net margin of roughly 11.9%, while maintaining a debt-to-equity ratio of about 0.6x and generating close to $1.1 billion in free cash flow. Kimberly-Clark saw fiscal 2025 revenue decline roughly 14.2% to nearly $17.2 billion due to structural changes, yet net income remained close to $2.0 billion with a net margin of roughly 11.7%, though its debt-to-equity ratio stood at approximately 4.9x and it generated nearly $1.6 billion in free cash flow. Church & Dwight trades at a forward price-to-earnings ratio of 25.7 times and a price-to-sales ratio of 3.7 times, while Kimberly-Clark trades at 14.7 times forward earnings and 2.1 times sales. The analysis concludes that Church & Dwight offers a better balance of long-term growth and dividend income, favoring it over Kimberly-Clark for investors seeking both.
Kimberly-Clark Outperforms S&P 500 and Nasdaq in 2026, Fueled by Recession Resistance and Kenvue Acquisition
Kimberly-Clark has risen 13.7% year to date, outpacing the S&P 500 and Nasdaq Composite, and offers a 4.5% dividend yield. The company’s recession-resistant portfolio of household brands like Huggies and Kleenex supports consistent demand, while management expects to recover input cost inflation and expand margins over time. A pending acquisition of consumer health company Kenvue, approved by shareholders, is set to close before year-end and is projected to deliver $2.1 billion in annual run rate synergies by the second year. Kimberly-Clark trades at 15.2 times consensus 2026 earnings estimates, well below its 10-year median price-to-earnings ratio of 21.9, and has raised its dividend for 54 consecutive years.
Two Dividend Kings—stocks with over 50 consecutive years of dividend increases—are highlighted as long-term buys. Payroll processor Automatic Data Processing, with 51 years of dividend growth, is trading more than 25% off its 2025 highs and offers a 2.7% yield, having raised its dividend through past recessions with unemployment as high as 14.8%. Consumer health company Kenvue, spun off from Johnson & Johnson in 2023, inherited Dividend King status and yields 4.3%, while paper products giant Kimberly-Clark, another Dividend King yielding 4.5%, is seeking regulatory approval to merge with Kenvue later this year. If the merger proceeds, Kenvue shareholders would receive $3.50 in cash and roughly one-seventh of a Kimberly-Clark share per Kenvue share, preserving the combined entity’s Dividend King status.
Kimberly-Clark Warns of $150-$170 Million Input Cost Hit If Oil Averages $100
Kimberly-Clark warned that if oil prices average around $100 per barrel in the second half of fiscal 2026, it could face incremental gross input costs of approximately $150-$170 million. The company has not incorporated this potential impact into its outlook due to ongoing uncertainty. Kimberly-Clark is relying on cost management, pricing discipline, and productivity initiatives to offset rising costs, having delivered 6% gross productivity for two consecutive years and achieving the same level in the first quarter of fiscal 2026. Management highlighted a robust pipeline of efficiency initiatives and noted that its previously announced $2 billion North America supply chain investment is progressing as planned. Approximately 80% of the company's overall cost basket is covered through contractual arrangements, programmatic hedging, and other measures, providing greater visibility into input costs.
Kenvue Stock May Be a Bargain Despite Mixed Valuation Signals
Kenvue stock has climbed 14.5% over the past month, but valuation metrics are split. A Discounted Cash Flow analysis estimates an intrinsic value of about $31.13 per share, implying the stock trades at roughly a 36.3% discount. However, Kenvue's price-to-earnings ratio of about 23.5 times is above the Personal Products industry average of roughly 18.7 times and above a model-implied fair P/E of about 21.3 times, suggesting overvaluation on an earnings basis. The planned $48.7 billion acquisition of Kenvue by Kimberly Clark adds deal execution and integration risk that may affect how investors price the stock.
Kimberly-Clark Plans $48.7 Billion Acquisition of Kenvue
Kimberly-Clark has announced a planned $48.7 billion acquisition of Kenvue, a deal that would integrate Kenvue into Kimberly-Clark's consumer products portfolio. Kenvue, which trades on the NYSE under the ticker KVUE, last closed at $19.33, with the stock up 2.8% over the past week and 11.4% over the past month. Over the past year the share price declined 3.2% and over three years it declined 15.0%. Investors are watching for updates on how the deal could affect Kenvue's operations, capital allocation, and brand priorities, as well as any guidance on margins, capital spending, and future capital returns.
Piper Sandler Raises Kimberly-Clark Price Target to $121 on Productivity Gains
Piper Sandler raised its price target on Kimberly-Clark Corporation to $121 from $115 while maintaining an Overweight rating. The firm cited manageable cost headwinds supported by solid productivity gains and a recent drop in oil prices. The new target reflects a multiple of approximately 16 times 2027 expected earnings per share, up from 15 times. Piper Sandler also noted expanded June merchandising and expects innovation to pick up in the latter half of 2026. The firm anticipates $150 million to $170 million in additional gross inflation assuming oil at $100 per barrel, compared with $80 currently, and said upside from the KVUE transaction will not be realized until 2028.
Kimberly-Clark’s dividend payout ratio has climbed near 80%, but the balance sheet tells a more reassuring story for income investors. The company paid $1.28 per share on July 2, 2026, extending its annual increase streak to 53 years, though free cash flow barely covered the dividend in fiscal 2025 at 0.99 times. However, shareholder equity jumped 79% to $1.502 billion in 2025 while total debt fell by $620 million, slashing the debt-to-equity ratio from 9.42 times to 4.86 times. In the first quarter of 2026, operating cash flow surged 128% year over year to $745 million, and adjusted earnings per share of $1.97 beat estimates. The pending $48.7 billion acquisition of Kenvue and a mid-2026 joint venture with Suzano are set to reshape the asset base, with management guiding for double-digit adjusted EPS growth.
Kimberly-Clark's Transformation Strategy and Dividend Strength Draw Bullish Thesis
A bullish thesis on Kimberly-Clark Corporation highlights the company's transformation into a higher-margin enterprise, supported by a 5.19% dividend yield and 54 consecutive years of dividend increases. Fourth-quarter 2025 results showed net income rising to $499 million and adjusted EPS growing 24% to $1.86, despite a slight sales decline. For the full year, sales reached $16.4 billion with 1.7% organic growth and adjusted EPS of $7.53. Management expects double-digit constant-currency adjusted EPS growth and approximately $2 billion in adjusted free cash flow, though risks include an elevated 83.07% payout ratio and category maturity.
KMB · Capital · Positive Transformation strategy, rising net income and EPS, strong dividend yield and history, and expected double-digit EPS growth and free cash flow.
Five High-Yielding Dividend Kings for Retirees to Buy and Hold Forever
Five Dividend Kings—companies with 50 or more consecutive years of dividend increases—offer retirees dependable income and stability as markets rotate away from volatile tech names. Altria yields 5.9% after its 57th consecutive dividend hike, while Kimberly-Clark pays nearly 5% after its shares fell 23% in 2025. Hormel Foods offers a 4.77% yield and is restructuring to cut costs, Sonoco Products pays 4.20% and makes constantly in-demand packaging, and Genuine Parts has raised its dividend for 69 consecutive years, trades at just 12 times forward earnings, and holds a Raymond James Strong Buy rating.
GPC · Capital · Positive Genuine Parts has raised its dividend for 69 consecutive years, trades at just 12 times forward earnings, and holds a Raymond James Strong Buy rating.
HRL · Capital · Positive Hormel Foods offers a 4.77% yield and is restructuring to cut costs.
KMB · Capital · Positive Kimberly-Clark pays nearly 5% after its shares fell 23% in 2025, making it a high-yield opportunity.
MO · Capital · Positive Altria yields 5.9% after its 57th consecutive dividend hike.
SON · Capital · Positive Sonoco Products pays 4.20% and makes constantly in-demand packaging.
Kimberly-Clark reports nine quarters of volume and share growth at dbAccess Global Consumer Conference
Kimberly-Clark Corporation highlighted nine consecutive quarters of volume and share growth at the 23rd annual dbAccess Global Consumer Conference on June 4, 2026. The company credited its Powering Care strategy for the momentum, noting that Huggies has been elevated to an 80 percent premium tier in the U.S. while value offerings are expanding globally. It is tracking ahead on its 3 billion dollar productivity program, having already delivered 56 percent of the target. International markets performed strongly, led by double-digit growth in Brazil, Indonesia, Vietnam, and Korea. The company also announced that Pull-Ups launched Learning Layer technology in Canada on June 8, 2026, a potty-training innovation that briefly delays fluid absorption to help toddlers learn wetness cues.
Three Consumer Staples Stocks to Consider for a $1,000 Investment Amid Market Uncertainty
The Motley Fool identifies Church & Dwight, Keurig Dr Pepper, and Kenvue as consumer staples companies offering predictable demand for a $1,000 investment during uncertain markets. Church & Dwight beat first-quarter 2026 guidance with 5% organic sales growth driven entirely by volume, and it acquired Miss Mouth's Messy Eater for $325 million in May. Keurig Dr Pepper's stock is down nearly 29% from its 2025 peak despite beating revenue estimates for four straight quarters, while its energy drink portfolio including Ghost, C4, Venom, and Black Rifle Energy is expected to generate well over $1 billion in annual retail sales. Kenvue's skin health and beauty division grew 8.4% in the first quarter of 2026, and its pending merger with Kimberly-Clark is expected to close in the second half of the year, creating one of the largest consumer health and personal care platforms globally.
KDP · Demand · Neutral Stock down 29% from peak despite beating revenue estimates; energy drink portfolio expected to generate over $1B in retail sales, but overall impact mixed.
KVUE · Demand · Positive Skin health and beauty division grew 8.4% in Q1 2026; pending merger with Kimberly-Clark.
KMB · Capital · Positive Pending merger with Kenvue expected to close in H2 2026, creating a large consumer health platform.
Piper Sandler Raises Kimberly-Clark Price Target to $121, Sees Long-Term Upside from Kenvue Deal
Piper Sandler raised its price target on Kimberly-Clark to $121 from $115 while reiterating an Overweight rating. The firm noted that potential benefits from the Kenvue deal are unlikely to appear in results until 2028 but could be meaningful over time. For now, Piper Sandler models only the legacy business because pro-forma segment details have not been provided. During the first-quarter 2026 earnings call, Chairman and CEO Michael Hsu said the company continued to gain market share in Baby Care, Women's Health, and Active Aging, and that the second-quarter product launch schedule would be one of the busiest in its history. CFO Nelson Urdaneta said a fire at the California distribution center is expected to reduce second-quarter revenue by about $20 million, with second-quarter earnings facing an estimated $50 million impact from Middle East conflict-related inflation and fire costs. Looking to the second half, Urdaneta stated that if oil prices average around $100 per barrel, Kimberly-Clark could see additional gross input cost pressures of roughly $150 million to $170 million.
Kenvue’s Pending $40 Billion Merger With Kimberly-Clark Creates a Near-$3 Per Share Arbitrage Opportunity
Kenvue, the consumer health spinoff from Johnson & Johnson, is trading around $18.32 per share, well below the $21.01 per share total consideration offered in its pending $40 billion mega-merger with Kimberly-Clark. The deal, already approved by shareholders of both companies but still subject to foreign regulatory approvals, would give Kenvue investors $3.50 in cash plus 0.14625 Kimberly-Clark shares for each Kenvue share held. The combined company expects to capture roughly $2.1 billion in run rate cost synergies by giving local markets full profit-and-loss ownership while leveraging Kimberly-Clark’s global supply chain. Kenvue, a Dividend King with 63 consecutive years of payout increases, currently yields 4.53% and owns iconic brands such as Tylenol, Listerine, Neutrogena, and Band-Aid, while its first-quarter revenue rose 4.5% year over year to $3.9 billion and earnings per share jumped 47% to $0.25.
KMB · Capital · Positive Kimberly-Clark is the acquirer in a $40B merger expected to generate $2.1B in cost synergies.
KVUE · Capital · Positive Kenvue shareholders receive $3.50 cash plus 0.14625 KMB shares per share, creating an arbitrage opportunity above current price.
USA
